Allogeneic T Cell Therapies Market Report 2026

The allogeneic t cell therapies market size has grown strongly in recent years. It will grow from $1.26 billion in 2025 to $1.38 billion in 2026 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to limitations of autologous therapies, early success of car-t treatments, rising cancer prevalence, advancements in immunotherapy research, hospital-based oncology expansion.

The allogeneic t cell therapies market size is expected to see strong growth in the next few years. It will grow to $1.98 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to demand for cost-effective cell therapies, expansion of oncology pipelines, improvements in donor matching, regulatory support for cell therapies, growth in specialty cancer centers. Major trends in the forecast period include shift toward off-the-shelf cell therapies, rising clinical trials in oncology, growing focus on scalable cell manufacturing, increased investment in cell engineering, expansion of specialized treatment centers.

The rising incidence of cancer is expected to drive the growth of the allogeneic T cell therapies market in the coming years. Cancer is a collection of diseases characterized by the uncontrolled growth and spread of abnormal cells within the body. The increase in cancer cases is attributed to factors such as longer life expectancy, lifestyle changes, environmental exposures, infections, genetic predispositions, and shifts in reproductive patterns, all of which contribute to a higher incidence and detection of the disease. Allogeneic T cell therapies are administered to cancer patients to target and destroy cancer cells by infusing genetically engineered donor T cells that recognize specific tumor antigens. For example, in May 2024, the National Cancer Institute, a US government agency, reported approximately 18.1 million cancer survivors in the United States. This number is projected to rise to 22.5 million by 2032. By 2040, the annual number of new cancer cases is expected to reach 29.9 million, with cancer-related deaths estimated at 15.3 million. Consequently, the rising number of cancer cases is fueling the growth of the allogeneic T cell therapies market.

Major companies in the allogeneic T cell therapies market are concentrating on developing advanced products, such as gene-edited donor-derived CAR-T and TCR T cell therapies, to strengthen their market position. Gene-edited donor-derived T cell therapies are immune-effector T cells obtained from healthy donors that are genetically modified (e.g., knockout of T cell receptor (TCR) and HLA genes, insertion of CAR/TCR constructs, inclusion of built-in safety switches) to produce universal off-the-shelf products. These therapies can be manufactured at scale, cryopreserved, and administered quickly without requiring patient-specific production. For example, in January 2024, Allogene Therapeutics, a US-based cell therapy company, revealed its 2024 platform vision focused on ALPHA3, the industry’s first pivotal trial of an allogeneic CAR-T program employing gene-editing technologies to eliminate the risk of graft-versus-host disease (GvHD) and enable rapid donor-based delivery. The product’s attributes include donor-derived T cells edited to remove endogenous TCR and HLA molecules to minimize host immune rejection and GvHD, a chimeric antigen receptor targeting a tumor antigen for rapid anti-cancer activity, and a cryopreserved ready-to-infuse format that reduces time to treatment compared to autologous therapies.

In January 2023, AstraZeneca plc, a UK-based pharmaceutical company, acquired Neogene Therapeutics Inc. for an undisclosed sum. This acquisition bolsters AstraZeneca’s oncology capabilities by incorporating Neogene’s expertise in developing advanced T-cell receptor (TCR) therapies aimed at cancer-specific mutations in solid tumors. It further strengthens the company’s capacity to advance innovative cell-based treatments that enhance outcomes for patients with hard-to-treat cancers. Neogene Therapeutics Inc. is a US-based biotechnology company specializing in allogeneic T-cell therapies.

Major companies operating in the allogeneic t cell therapies market are Allogene Therapeutics Inc., Cellectis SA, Fate Therapeutics Inc., Poseida Therapeutics Inc., Atara Biotherapeutics Inc., Autolus Therapeutics Plc, Adaptimmune Therapeutics Plc, Immatics NV, Medigene AG, Celyad Oncology SA, Bristol-Myers Squibb Company, Novartis AG, Gilead Sciences Inc., Sangamo Therapeutics Inc., MaxCyte Inc., Tessa Therapeutics Pte Ltd., Cell Medica Inc., Bellicum Pharmaceuticals Inc., Enlivex Therapeutics Ltd., Sorrento Therapeutics Inc.

North America was the largest region in the allogeneic T cell therapies market in 2025. The regions covered in the allogeneic t cell therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the allogeneic t cell therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the allogeneic t cell therapies market by increasing the cost of imported bioprocessing equipment, viral vectors, and cell culture reagents essential for therapy manufacturing. These effects are most pronounced in CAR t and tcr therapy segments and in regions such as north america and europe, where advanced cell therapy production and cross-border sourcing of critical inputs are common. Higher input costs have placed pricing pressure on cancer treatment programs in hospitals and specialty clinics. However, tariffs have also encouraged domestic manufacturing of cell therapy materials, supporting supply chain resilience and localized production capabilities.

The allogeneic t cell therapies market research report is one of a series of new reports that provides allogeneic t cell therapies market statistics, including allogeneic t cell therapies industry global market size, regional shares, competitors with a allogeneic t cell therapies market share, detailed allogeneic t cell therapies market segments, market trends and opportunities, and any further data you may need to thrive in the allogeneic t cell therapies industry. This allogeneic t cell therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Allogeneic T cell therapies involve a medical treatment in which T cells, an essential part of the immune system, are collected from a donor instead of the patient and utilized to identify and eliminate cancer cells in the recipient. These therapies are mainly applied in treating different types of cancers, especially those that are challenging to manage with standard treatments.

Allogeneic T cell therapies primarily consist of chimeric antigen receptor (CAR) T cell therapies and T cell receptor (TCR) therapies. Chimeric antigen receptor (CAR) T-cell therapies are a form of immunotherapy in which a patient's T-cells are genetically engineered to identify and eliminate cancer cells. This approach involves modifying T-cells to detect specific proteins present on cancer cells. The antigen targets for these therapies include CD19, CD20, EgfrvIII, GD2, CD22, CD30, CD33, Meso, HER1, among others. These therapies are applied for therapeutic purposes such as cancer, autoimmune disorders, infectious diseases, and more, and are administered by end users including hospitals, specialty clinics, research institutions, and others.

The allogeneic T cell therapies market includes revenues earned by entities providing services such as allogeneic CAR-t cell therapy, allogeneic TCR-t cell therapy, allogeneic NK or T cell therapy, off-the-shelf allogeneic t cell therapy, allogeneic virus-specific t cell therapy, and universal donor t cell therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.